Karen H Costenbader
Overview
Explore the profile of Karen H Costenbader including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
282
Citations
12989
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Sasaki T, Sowerby J, Xiao Y, Wang R, Marks K, Horisberger A, et al.
bioRxiv
. 2025 Feb;
PMID: 39974998
Pathologic T cell-B cell interactions drive disease in systemic lupus erythematosus (SLE). The T cells that activate B cell responses include T peripheral helper (Tph) and T follicular helper (Tfh)...
3.
Nestor J, Zhang L, Choi H, Costenbader K, Jorge A
Arthritis Rheumatol
. 2025 Feb;
PMID: 39957484
No abstract available.
4.
Vanni K, McCarter K, Wang X, Duffy C, Cruz J, Wobma H, et al.
Lancet Rheumatol
. 2025 Jan;
PMID: 39889722
No abstract available.
5.
Deane K, Holers V, Emery P, Mankia K, El-Gabalawy H, Sparks J, et al.
Ann Rheum Dis
. 2025 Jan;
84(1):14-28.
PMID: 39874228
Multiple clinical trials for rheumatoid arthritis (RA) prevention have been completed. Here, we set out to report on the lessons learnt from these studies. Researchers who conducted RA prevention trials...
6.
Kim Y, Koopman J, Choi M, Feldman C, Costenbader K
Arthritis Care Res (Hoboken)
. 2025 Jan;
PMID: 39800912
Systemic lupus erythematosus (SLE) is a serious multisystem autoimmune disease, marked by alarming sociodemographic inequities. In the United States and around the world, social disadvantage is strongly tied to higher...
7.
Parks C, Leyzarovich D, Hamra G, Costenbader K, Chen D, Hofmann J, et al.
Sci Rep
. 2024 Dec;
14(1):29978.
PMID: 39622868
Pesticides and farming have been associated with increased rheumatoid arthritis (RA) risk, but the role of specific pesticides remains unknown. We examined RA risk among licensed pesticide applicators (97% white...
8.
Oakes E, Ellrodt J, Guan H, Yee J, Choi M, Costenbader K
Clin Rheumatol
. 2024 Oct;
43(12):3839-3847.
PMID: 39448504
Background: Systemic autoimmune rheumatic disease (SARD) patients have been excluded from sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials given putative risks, but this risk magnitude is unknown. We aimed to quantify...
9.
Ma K, Lo J, Kyttaris V, Tsokos G, Costenbader K
Arthritis Rheumatol
. 2024 Oct;
PMID: 39431397
Objective: Patients with systemic lupus erythematosus (SLE) were excluded from sodium-glucose cotransporter 2 inhibitors (SGLT2i) clinical trials. It is unknown whether the cardiorenal benefits of SGLT2i extend to patients with...
10.
Choi M, Costenbader K, Fritzler M
Front Immunol
. 2024 Sep;
15:1456145.
PMID: 39318630
Introduction: Despite progress in our understanding of disease pathogenesis for systemic autoimmune rheumatic diseases (SARD), these diseases are still associated with high morbidity, disability, and mortality. Much of the strongest...